South Korea’sBoryung Pharmaceutical announced on May 2 that it has launched its flagship hypertension drug Kanarb in the Philippines.
“With our experience of Kanarb’s success in Korea, we aim to make it the family No. 1 hypertension drug line in South Asia and Latin America,” said Boryung Pharmaceutical CEO Lee Sam-soo.
Boryung Pharmaceutical’s family brands which include it’s flagship hypertension drug Kanarb, are new drugs and complexes that include substances used for treating hyper blood pressure and hyperlipidemia.
Last year, the firm launched Kanarb family drugs in Singapore and Malaysia. The company also in September 2014 first entered the Mexican market with its drug Arahkor. So far, the company has signed a license-out deal for the Kanarb family brands with partners in 51 different countries and has gained sales approval in 18 countries.
Lee also added that Boryung Pharmaceutical will conduct aggressive marketing using its clinical trials results.
Meanwhile Boryung Pharmaceutical also recently established a new production facility in Yesan, South Chungcheong Province, to prepare for the demand surge as it expands its presence globally. It projects the Kanarb brand’s sales to reach over 200 billion won this year.
Kanarb, in which the company injected around 50 billion won over the course of 12 years to develop, obtained a domestic marketing license in 2010 as the 15th novel drug here.
By Song Seung-hyun (firstname.lastname@example.org)